Copyright 2022 SPARK

Roger Newton is Executive Chairman and Chief Scientific Officer of Esperion Therapeutics

Tim Mayleben is President and Chief Executive Officer of Esperion Therapeutics

Esperion Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density, lipoprotein cholesterol (LDL-C) lowering therapies for treatment of hypercholesterolemia and other cardiometabolic risk markers.

In their conversation with Paul Krutko, president and CEO of Ann Arbor SPARK, Roger (who is also a SPARK board member) and Tim discuss Esperion’s focus, being acquired by and then re-emerging from Pfizer, and how economic development organizations like MEDC have assisted Esperion with its growth.

Listen to the podcast here. 

Esperion-Podcast-photo